Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1322-1329, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Treon, S. P.
Right arrow Articles by Chabner, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Treon, S. P.
Right arrow Articles by Chabner, B. A.

Clinical Chemistry, Vol 42, 1322-1329, Copyright © 1996 by American Association for Clinical Chemistry

Concepts in use of high-dose methotrexate therapy

SP Treon and BA Chabner
Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.

In cancer chemotherapy, routine monitoring of drug concentrations has been practical only for methotrexate (MTX). The primary setting for pharmacokinetic monitoring of MTX is its use in high doses (HDMTX) for adjuvant therapy of osteosarcoma, for single-agent treatment of intracranial lymphomas, and in combination therapy of childhood leukemia as well as adult and pediatric non-Hodgkin lymphomas. Typically, HDMTX is infused in doses of 3-15 g/m2 over a period of 6-24 h. Precautions must be taken to ensure a high urine flow and an alkaline urine pH, so as to prevent precipitation of MTX in urine. Patients with decreased renal function, advanced in age, and taking nonsteroidal anti-inflammatory drugs or nephrotoxic agents are at increased risk of developing renal dysfunction during MTX infusion, thus being placed at high risk for toxicity. At the end of HDMTX infusion, and periodically thereafter for 24-48 h, drug concentrations are measured to assure that the disappearance rate of MTX from plasma is occurring at a normal rate. Also, at the end of HDMTX infusion, the patient is given leucovorin (5-formyl-tetrahydrofolic acid; LV), which replenishes intracellular stores of reduced folate and attenuates the toxicity secondary to HDMTX. In the presence of inappropriately high concentrations of MTX, routine doses of LV will be ineffective; the dose of LV required must be increased in proportion to the MTX concentration it faces in plasma. In practice, routine monitoring of plasma MTX concentrations allows early detection of abnormal clearance, as well as institution of early and effective countermeasures, including the use of increased and prolonged LV rescue.


The following articles in journals at HighWire Press have cited this article:


Home page
 GutHome page
G B McDonald and D Frieze
A problem-oriented approach to liver disease in oncology patients
Gut, July 1, 2008; 57(7): 987 - 1003.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. M. Spees, T. P.F. Gade, G. Yang, W. P. Tong, W. G. Bornmann, R. Gorlick, and J. A. Koutcher
An 19F Magnetic Resonance-Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle
Clin. Cancer Res., February 15, 2005; 11(4): 1454 - 1461.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. Peyriere, M. Cociglio, G. Margueritte, C. Vallat, J.-P. Blayac, and D. Hillaire-Buys
Optimal Management of Methotrexate Intoxication in a Child with Osteosarcoma
Ann. Pharmacother., March 1, 2004; 38(3): 422 - 427.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Tilly, E. Lepage, B. Coiffier, M. Blanc, R. Herbrecht, A. Bosly, M. Attal, G. Fillet, C. Guettier, T. J. Molina, et al.
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
Blood, December 15, 2003; 102(13): 4284 - 4289.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. S H Lam and R. J Ignoffo
A guide to clinically relevant drug interactions in oncology
Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85.
[Abstract] [PDF]

Home page
 Anesth. Analg.Home page
S. Suresh, S. Lozono, and S. C. Hall
Large-Dose Intravenous Methotrexate-Induced Cutaneous Toxicity: Can Oral Magnesium Oxide Reduce Pain?
Anesth. Analg., May 1, 2003; 96(5): 1413 - 1414.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. Farrugia, G. W. Aherne, L. Brunton, S. J. Clarke, and A. L. Jackman
Leucovorin Rescue from Raltitrexed (Tomudex)-induced Antiproliferative Effects: In Vitro Cell Line and in Vivo Mouse Studies
Clin. Cancer Res., September 1, 2000; 6(9): 3646 - 3656.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
B. C. Widemann, F. M. Balis, and P. C. Adamson
Dihydrofolate Reductase Enzyme Inhibition Assay for Plasma Methotrexate Determination Using a 96-Well Microplate Reader
Clin. Chem., February 1, 1999; 45(2): 223 - 228.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.